Paul Boutros, professor of human genetics and of urology, is pushing forward a technology that may result in a comprehensive, fast and inexpensive genetic test that predicts which cases of prostate cancer will be aggressive, which is a current challenge in treating the disease. The core idea is to combine all existing genetic assessments for prostate cancer in a single test. UCLA research teams hastening progress in areas from cancer treatment to clean energy have received a philanthropic boost from the Noble Family Innovation Fund. Created through a three-year, $10 million commitment to the California NanoSystems Institute at UCLA, the Noble Fund supports basic and translational investigations into phenomena occurring on the nanoscale — that is, billionths of a meter. A primary focus is on projects with the potential to launch knowledge-driven commercial enterprises and benefit society. For the second year of funding, the CNSI kicked off a competitive process with the solicitation of letters of intent in February 2022. Grants of up to $250,000 and two years were awarded to a dozen teams pursuing high-risk, high-reward science and engineering For more information about the Noble fund please go here: https://cnsi.ucla.edu/noble-fund/